Sulforaphane and Alzheimer's

I have watched several family members—great aunts, great uncles—slowly fade into oblivion. Lose their identity. Forget their history. And, above all, forget us. That kind of experience leaves its mark. And it pushes you, almost with fear, to seek information and try to understand what has happened.

In several articles, from different sources, I have found references to sulforaphane. Almost always with the same word next to it: "promising." A dangerous word, because it can sell a lot and deliver little.

This article is the result of seriously reading the scientific literature on sulforaphane and cognitive conditions, particularly Alzheimer's. I have tried to compile here the available data, the reasonably documented mechanisms, the existing human studies, the clinical trial currently underway, and the large gray areas that research has not yet resolved.

Why Alzheimer's Needs New Solutions

Dementia currently affects about 55 million people worldwide, according to data from the World Health Organization. The number grows every year because the population is aging faster than therapeutic advances.

The disease is characterized by two well-identified and documented pathological hallmarks.
Added to this is a third decisive element: chronic oxidative stress and neuroinflammation, two processes that amplify the neurodegenerative cascade and are detected in the brain decades before the first clinical symptoms.

That "decades before" is the key. When daily forgetfulness appears, when a person begins to struggle to find words, when they confuse familiar names, the disease has already been at work for some time. This is why current research has shifted from late symptomatic treatment to the search for molecules capable of acting in the preclinical phase. Safe, accessible molecules, ideally present in the diet. Sulforaphane presents an interesting profile, although its clinical preventive efficacy in humans has not yet been demonstrated.

What is sulforaphane and where does it come from?

Sulforaphane is an isothiocyanate. A sulfur-containing compound that does not exist as such in the intact plant but forms when the plant tissue is damaged. In cruciferous vegetables (broccoli, kale, Brussels sprouts, cabbage, arugula, watercress, and especially broccoli sprouts), a precursor molecule called glucoraphanin is stored. When we chew, cut, or crush the vegetable, an enzyme called myrosinase comes into contact with glucoraphanin and converts it into sulforaphane.

Broccoli sprouts concentrate between 20 and 100 times more glucoraphanin than mature broccoli, depending on the variety and growing conditions. This difference is enormous and explains why most serious clinical studies have been conducted with sprouts, not with the broccoli head from the supermarket. There is another, even more inconvenient reason: the actual glucoraphanin content of conventional broccoli varies drastically from one harvest to another and degrades with storage, something we analyze in detail in our article on glucoraphanin in broccoli: variety, cultivation, and actual concentration.

This matters because the question "Does sulforaphane work for Alzheimer's?" depends entirely on how much sulforaphane is actually consumed. Not on how much is listed on a label.

How sulforaphane acts in the brain: the Nrf2 pathway

The mechanism of action of sulforaphane is well characterized at the molecular level, which distinguishes this molecule from other plant compounds with more diffuse effects.

Its main target is a protein called Keap1. Sulforaphane reacts with a specific cysteine residue (Cys-151) and blocks Keap1's ability to tag and degrade another protein: the transcription factor Nrf2. When Nrf2 stops degrading, it stabilizes, enters the cell nucleus, and activates the transcription of over two hundred cytoprotective genes. These include NQO1, heme oxygenase-1, glutathione synthase, superoxide dismutase, and catalase. All are enzymes that the brain needs to defend against oxidative stress.

The Keap1-Nrf2-ARE pathway is not a hypothesis. It is one of the most studied endogenous antioxidant systems of the last decade. And it is precisely this pathway that weakens with age and is found depressed in the brains of post-mortem Alzheimer's patients. The fact that sulforaphane robustly activates it has prompted so many research teams to study it in neurodegeneration models.

Sulforaphane and beta-amyloid: the role of BACE1 inhibition

Here, the research becomes more specific. And more interesting.

For the toxic beta-amyloid peptide to form, an enzyme called BACE1 (beta-secretase 1) must cleave the amyloid precursor protein. If BACE1 is inhibited, Aβ production decreases. Large pharmaceutical companies have been trying to develop pharmacological BACE1 inhibitors for over fifteen years. Almost all have failed in clinical trials due to adverse effects.

In 2019, a study published in Proceedings of the National Academy of Sciences (PNAS) demonstrated that Nrf2 activation directly represses BACE1 expression in murine models of Alzheimer's, and that this repression translates into measurable cognitive improvement. Subsequent work by Youn and collaborators, published in Nutrients in 2020, identified sulforaphane as a potent BACE1 inhibitor through kinetic and computational studies.

When one has seen, as I have, a great-aunt who no longer recognizes her own nephews, one quickly understands why any intervention that acts decades before symptoms deserves attention. Not to cure what is already established, which is another story, but to alter the silent trajectory of the disease in the phase when no one has symptoms.

Sulforaphane and tau protein: autophagy as a clearing pathway

The second major hallmark of Alzheimer's is the accumulation of hyperphosphorylated tau. Neurons have mechanisms to recycle and eliminate misfolded proteins; one of these mechanisms is autophagy.

A study by Jo and collaborators, published in Nature Communications in 2014, demonstrated that Nrf2 activation induces the expression of an autophagic adapter called NDP52, capable of tagging phosphorylated tau protein for degradation. That is, Nrf2 helps the brain clear tau, not just produce less amyloid.

Lee and collaborators described a complementary mechanism in 2018: sulforaphane increases the expression of a co-chaperone called CHIP, which works with heat shock protein HSP70 to identify altered proteins and direct them towards proteasomal degradation. In Alzheimer's models, mice treated with sulforaphane showed fewer amyloid plaques and less pathological tau.

It's important to be precise here: these findings come from animal and cellular models. What happens in a mouse neuron does not exactly replicate what happens in a human neuron. But the convergence of mechanisms—less amyloid production via BACE1, more tau clearance via autophagy—provides a coherent biological hypothesis. Coherent, not proven.

Sulforaphane against neuroinflammation

The third dimension, almost always overlooked in popular science articles, is neuroinflammation.

The brain has its own immune system, largely formed by cells called microglia. When microglia are chronically activated, they produce proinflammatory cytokines (TNF-α, IL-1β, IL-6) that damage surrounding neurons. This chronic activation is one of the central processes in the pathogenesis of Alzheimer's.

A study by Qin and collaborators in Pharmacological Research (2018) describes how sulforaphane inhibits the NF-κB pathway, the main molecular switch of the inflammatory response, by inducing heme oxygenase-1. Even more interesting: a study by Chilakala and collaborators in Neuroscience (2020) showed that sulforaphane restores the phagocytic activity of microglia when it had been altered by beta-amyloid oligomers. In other words, it not only reduces harmful inflammation but also restores the brain's immune cells' ability to clean up.

What animal studies show

The most comprehensive review to date on sulforaphane and neurodegenerative diseases was signed by Schepici, Bramanti, and Mazzon in the International Journal of Molecular Sciences in 2020 (DOI: 10.3390/ijms21228637). The results of the main animal models of Alzheimer's are summarized below.

What matters from this table is not any individual result. What matters is the convergence: seven different models, five distinct research teams, varied doses and administration routes, all pointing in the same direction. It is not an isolated finding from a single laboratory.

This does not mean that the effect translates to humans. The history of neurology is full of molecules that worked in mice and failed in people. But it means that the biological hypothesis is well supported in preclinical studies and warrants serious clinical studies.

The first relevant human study: Sedlak 2018

As far as scientific literature can tell at the time of writing this article, there is only one published study that directly measures the effect of sulforaphane in the living human brain.

It was authored by the Sedlak team at Johns Hopkins University and published in Molecular Neuropsychiatry in 2018 (DOI: 10.1159/000487639). It is a small, pilot study in healthy subjects who received oral sulforaphane for seven days. Researchers measured brain glutathione levels using 7 Tesla magnetic resonance spectroscopy, a technique that allows quantifying metabolites in specific regions of the living brain without opening it.

Three results are worth noting:

• Sulforaphane significantly increased blood glutathione levels.

• Brain glutathione consistently increased in the three regions measured: anterior cingulate cortex, hippocampus, and thalamus.

• There was a positive correlation between blood and thalamic glutathione levels after supplementation.

Why this matters in Alzheimer's

Glutathione is the main intracellular antioxidant in the central nervous system. Its depletion is one of the most reliable early markers of neurodegeneration and is reduced in patients with mild cognitive impairment long before a clinical diagnosis of Alzheimer's.

What this study does not prove

No Alzheimer's patients participated. No cognitive outcomes were measured. The sample was small. It is a human mechanistic study, not a demonstration of clinical efficacy. To call it "evidence that sulforaphane works against Alzheimer's" would be dishonest. But to ignore it, too.

The ongoing clinical trial: NCT04213391

There is one piece of information that no popular science article in Spanish mentions, and which significantly changes the picture: there is a randomized, double-blind, placebo-controlled clinical trial specifically studying sulforaphane in Alzheimer's patients.

It is registered on ClinicalTrials.gov with the code NCT04213391. It is sponsored by the Second Affiliated Hospital of Zhejiang University in China. It includes 160 patients with prodromal to mild Alzheimer's, divided into two arms of 80 people. The treatment duration is 24 weeks. The dose is 2,550 mg per day. Endpoints include standardized neuropsychological scales and biomarkers in biological samples.

While we await the results, those of us who have seen a family member progressively lose their personal history know that every year counts. Every serious new line of research matters. Every reasonably documented mechanism deserves follow-up. The trial has not yet published data. When it does, whatever the outcome, we will for the first time have direct clinical evidence to answer the question in this article's title.

Until then, it is honest to state what is known and what is still missing.

Levels of evidence: established, emerging, and unproven

To avoid the confusion that dominates so many popular science articles, it is important to lay the cards on the table. This table summarizes the actual state of the evidence.

This is exactly the information a doctor, nutritionist, or well-informed family member needs to make reasonable decisions. Neither euphoria nor rejection. Just facts.

Sulforaphane in the diet: broccoli sprouts, bioavailability, and everyday reality

A natural question arises after reading all of the above: how much broccoli would one have to eat to approach the studied doses?

The short answer: considerably more than people think, and with far more nuances than usually appear.

The actual amount of sulforaphane produced by the same gram of broccoli depends on three variables that almost no one measures. First, the initial glucoraphanin content, which varies up to tenfold between crops and degrades during storage. Second, myrosinase activity, which is destroyed by heat; boiling broccoli in water for more than two or three minutes practically eliminates all conversion. Third, the presence of intestinal or microbial myrosinase, which in some individuals partially compensates for the loss of the plant enzyme and in others does not.

That's why serious clinical studies use standardized extracts or lyophilized broccoli sprouts with controlled doses. They don't use "a plate of steamed broccoli."

I say this from the experience of accompanying several family members through this process: consistently incorporating cruciferous vegetables into the family diet is not a cure. But it is one of the few accessible, inexpensive, and contraindication-free actions that scientific literature supports as part of a neuroprotective dietary pattern. If you have to choose, broccoli sprouts over mature broccoli; raw or lightly steamed over heavily cooked; combined with mustard seeds (which provide additional myrosinase) over alone. We analyze this in detail in our article on the nutritional loss of vegetables, and it applies directly here: the ingredient can be good, but the dish can be bad if it's not prepared with a minimum of care.

Frequently Asked Questions about Sulforaphane and Alzheimer's

Does sulforaphane cure Alzheimer's?

No. No clinical study has shown that sulforaphane cures or reverses Alzheimer's disease in humans. Current research is studying its possible role in prevention and in modulating pathological mechanisms such as oxidative stress, beta-amyloid production, and neuroinflammation.

What dose of sulforaphane has been studied for Alzheimer's?

The ongoing clinical trial (NCT04213391) uses 2,550 mg daily for 24 weeks in patients with prodromal to mild Alzheimer's. Animal studies use highly variable equivalent doses, between 1 and 50 mg/kg depending on the model. These doses are not directly extrapolable to dietary consumption.

Is eating broccoli the same as taking a sulforaphane supplement?

No. The amount of sulforaphane obtained from conventional broccoli varies enormously depending on the variety, storage, and, above all, the cooking method. Clinical studies typically use broccoli sprouts or standardized extracts, not cooked mature broccoli.

When will the results of clinical trial NCT04213391 be published?

The trial has not published results as of the date this article was written. ClinicalTrials.gov is the official source to consult the updated status.

Are there risks in consuming sulforaphane from the diet?

Sulforaphane from cruciferous vegetables is considered safe at typical dietary consumption doses. At high doses in supplement form, people with thyroid problems, pregnant women, or those taking anticoagulants should consult a healthcare professional before supplementing.

Why is myrosinase so important for obtaining sulforaphane?

Because glucoraphanin in broccoli is not active on its own; it needs the enzyme myrosinase to be transformed into sulforaphane. This enzyme is destroyed by intense heat. Cooking broccoli heavily drastically reduces the actual amount of available sulforaphane.

Conclusion

When you see a great-uncle lose the connections that wove his world for decades, you realize that preventing cognitive decline is not an abstract issue. It is built silently, over decades, long before the first symptoms. And it is built by adding many small factors, none of which is the solution by itself.

Regarding sulforaphane, the reasonable position seems to be this. The biology is consistent. Animal studies are convergent. The only serious human mechanistic study confirms that the molecule indeed elevates brain glutathione. There is a clinical trial underway that will provide the first direct answer. Meanwhile, including cruciferous vegetables and broccoli sprouts in a varied diet is a decision supported by scientific evidence for general health, although no serious article can claim that it "prevents Alzheimer's."

That is exactly what the evidence allows us to say today.